News Merck MS tablet set for wider use by NHS in England Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad.
News Merck's oral MS drug finally gets FDA okay Merck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after being turned down by the US regulator.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
